Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1989 1
1990 1
1991 2
1994 1
1995 1
2004 1
2005 2
2006 1
2008 2
2009 2
2010 3
2011 2
2012 5
2013 7
2014 2
2015 5
2016 6
2017 6
2018 7
2019 3
2020 1
2021 4
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Pulmonary hamartoma syndrome.
Gabrail NY, Zara BY. Gabrail NY, et al. Chest. 1990 Apr;97(4):962-5. doi: 10.1378/chest.97.4.962. Chest. 1990. PMID: 2323262
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.
Garcia-Manero G, McCloskey J, Griffiths EA, Yee KWL, Zeidan AM, Al-Kali A, Deeg HJ, Patel PA, Sabloff M, Keating MM, Zhu N, Gabrail NY, Fazal S, Maly J, Odenike O, Kantarjian H, DeZern AE, O'Connell CL, Roboz GJ, Busque L, Buckstein R, Amin H, Randhawa J, Leber B, Shastri A, Dao KH, Oganesian A, Hao Y, Keer HN, Azab M, Savona MR. Garcia-Manero G, et al. Among authors: gabrail ny. Lancet Haematol. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1. Lancet Haematol. 2024. PMID: 38135371 Clinical Trial.
Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.
Haymaker C, Johnson DH, Murthy R, Bentebibel SE, Uemura MI, Hudgens CW, Safa H, James M, Andtbacka RHI, Johnson DB, Shaheen M, Davies MA, Rahimian S, Chunduru SK, Milton DR, Tetzlaff MT, Overwijk WW, Hwu P, Gabrail N, Agrawal S, Doolittle G, Puzanov I, Markowitz J, Bernatchez C, Diab A. Haymaker C, et al. Among authors: gabrail n. Cancer Discov. 2021 Aug;11(8):1996-2013. doi: 10.1158/2159-8290.CD-20-1546. Epub 2021 Mar 11. Cancer Discov. 2021. PMID: 33707233 Free PMC article. Clinical Trial.
Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen.
Afari J, Spektor TM, Turner C, Cohen A, Bessudo A, Jhangiani H, Gabrail N, Kubba S, Neidhart JD, Eshaghian S, Swift RA, Eades BM, Kim C, Kim S, Vescio R, Berenson JR. Afari J, et al. Among authors: gabrail n. Exp Hematol. 2022 Oct;114:54-60. doi: 10.1016/j.exphem.2022.07.303. Epub 2022 Aug 4. Exp Hematol. 2022. PMID: 35934183 Free article. No abstract available.
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Macé S, Corzo KP, Leleu X. Mikhael J, et al. Among authors: gabrail n. Blood Cancer J. 2021 May 12;11(5):89. doi: 10.1038/s41408-021-00478-4. Blood Cancer J. 2021. PMID: 33980831 Free PMC article. Clinical Trial. No abstract available.
Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens.
Niesvizky R, Flinn IW, Rifkin R, Gabrail N, Charu V, Clowney B, Essell J, Gaffar Y, Warr T, Neuwirth R, Zhu Y, Elliott J, Esseltine DL, Niculescu L, Reeves J. Niesvizky R, et al. Among authors: gabrail n. J Clin Oncol. 2015 Nov 20;33(33):3921-9. doi: 10.1200/JCO.2014.58.7618. Epub 2015 Jun 8. J Clin Oncol. 2015. PMID: 26056177 Clinical Trial.
61 results